Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial

William N. William, Lei Feng, Renata Ferrarotto, Lawrence Ginsberg, Merrill Kies, Scott Lippman, Bonnie Glisson, Edward S. Kim

Research output: Contribution to journalArticlepeer-review

99 Scopus citations

Abstract

Background Preclinical data demonstrate a key role for the epidermal growth factor receptor (EGFR) in the carcinogenesis of cutaneous squamous cell carcinomas (CSCCs). There are, however, limited data on the efficacy of EGFR inhibitors in incurable, recurrent, and/or metastatic CSCC. Objective To determine the response rate to gefitinib in patients with CSCC not amenable to curative therapy including surgery or radiation. Methods This was a single-arm phase II study. A total of 40 patients were treated with gefitinib, 250 mg orally daily, until disease progression or intolerable toxicities. The prespecified target response rate of interest was 20%. Results The overall response rate was 16% (95% confidence interval, 0.06-0.32; 6 partial responses in 37 evaluable patients). An additional 13 patients (35%) had stable disease at 8 weeks. The median durations of response and progression-free survival were 31.4 months (95% confidence interval, 3.91-not applicable) and 3.8 months (95% confidence interval, 2.2-5.7), respectively. The side effect profile was consistent with the previous experience with gefitinib in other tumor types. Limitations This was a single-institution, single-arm study. The prespecified target response rate was not met. Conclusion Gefitinib demonstrated modest activity in incurable CSCC, with a favorable adverse event profile.

Original languageEnglish (US)
Pages (from-to)1110-1113.e2
JournalJournal of the American Academy of Dermatology
Volume77
Issue number6
DOIs
StatePublished - Dec 2017
Externally publishedYes

Keywords

  • clinical trial
  • cutaneous squamous cell carcinoma
  • epidermal growth factor receptor
  • gefitinib
  • skin cancer
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial'. Together they form a unique fingerprint.

Cite this